Cargando…

Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model

The SARS-CoV2 Omicron variants have acquired new Spike mutations leading to escape from the most of the currently available monoclonal antibody treatments reducing the options for patients suffering from severe Covid-19. Recently, both in vitro and in vivo data have suggested that Sotrovimab could r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hérate, Cécile, Marlin, Romain, Touret, Franck, Dereuddre-Bosquet, Nathalie, Donati, Flora, Relouzat, Francis, Junges, Laura, Galhaut, Mathilde, Dehan, Océane, Sconosciuti, Quentin, Nougairède, Antoine, de Lamballerie, Xavier, van der Werf, Sylvie, Le Grand, Roger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228175/ https://www.ncbi.nlm.nih.gov/pubmed/37287613 http://dx.doi.org/10.1016/j.heliyon.2023.e16664

Ejemplares similares

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2023)

Impact of variants of concern on SARS-CoV-2 viral dynamics in non-human primates
por: Marc, Aurélien, et al.
Publicado: (2023)

Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients
por: Bruel, Timothée, et al.
Publicado: (2023)

A Case Study to Dissect Immunity to SARS-CoV-2 in a Neonate Nonhuman Primate Model
por: Fovet, Claire-Maëlle, et al.
Publicado: (2022)

Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection
por: Jiang, Xiao-Lin, et al.
Publicado: (2023)

Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys
por: Fenwick, Craig, et al.
Publicado: (2022)

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates
por: Marlin, Romain, et al.
Publicado: (2022)

SARS-CoV-2 viral dynamics in non-human primates
por: Gonçalves, Antonio, et al.
Publicado: (2021)

Emergence BQ.1 and BQ.1.1 as newly identified omicron subvariants: current scenario and future outlook – an update
por: Akash, Shopnil, et al.
Publicado: (2023)

Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines
por: Li, Dedong, et al.
Publicado: (2023)

Sotrovimab for COVID-19
Publicado: (2021)

Sotrovimab: First Approval
por: Heo, Young-A
Publicado: (2022)

In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5
por: Touret, Franck, et al.
Publicado: (2022)

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages
por: Touret, Franck, et al.
Publicado: (2023)

Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on Spike and provides antiviral protection through inhalation-based delivery in non-human primates
por: Hermet, Paule, et al.
Publicado: (2023)

Live Zika virus chimeric vaccine candidate based on a yellow fever 17-D attenuated backbone
por: Touret, Franck, et al.
Publicado: (2018)

Complete Coding Sequences of Two Dengue Virus Type 2 Strains Isolated from an Outbreak in Burkina Faso in 2016
por: Baronti, Cécile, et al.
Publicado: (2017)

Omicron sublineage BQ.1.1 resistance to monoclonal antibodies
por: Arora, Prerna, et al.
Publicado: (2023)

Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
por: Cicchitto, Gaetano, et al.
Publicado: (2022)

Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection
por: Alexandre, Marie, et al.
Publicado: (2022)

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

A rapid surge of the Omicron variant’s sublineages BQ.1/BQ.1.1: A matter of worry amid the crucial trajectory of the COVID-19 pandemic
por: Dhawan, Manish, et al.
Publicado: (2023)

Computed tomography and [(18)F]-FDG PET imaging provide additional readouts for COVID-19 pathogenesis and therapies evaluation in non-human primates
por: Naninck, Thibaut, et al.
Publicado: (2022)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2
por: Martin-Blondel, Guillaume, et al.
Publicado: (2022)

Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection
por: Chavarot, Nathalie, et al.
Publicado: (2022)

Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
por: Wu, Mary Y., et al.
Publicado: (2023)

Impaired humoral immunity to BQ.1.1 in convalescent and vaccinated patients
por: Dewald, Felix, et al.
Publicado: (2023)

Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2
por: Zhu, Airu, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children
por: Bellusci, Lorenza, et al.
Publicado: (2023)

Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques
por: Marlin, Romain, et al.
Publicado: (2021)

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication
por: Touret, Franck, et al.
Publicado: (2020)

Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques
por: Zabaleta, Nerea, et al.
Publicado: (2022)

Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab
por: Vellas, Camille, et al.
Publicado: (2022)

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients
por: Destras, Grégory, et al.
Publicado: (2022)

Further quantitative in silico analysis of SARS-CoV-2 S-RBD Omicron BA.4, BA.5, BA.2.75, BQ.1, and BQ.1.1 transmissibility
por: Hanai, Toshihiko
Publicado: (2023)

Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2
por: Qu, Panke, et al.
Publicado: (2023)

Niclosamide shows strong antiviral activity in a human airway model of SARS-CoV-2 infection and a conserved potency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta variant (B.1.617.2)
por: Weiss, Anne, et al.
Publicado: (2021)

Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2
por: Qu, Panke, et al.
Publicado: (2022)

Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants
por: Bellusci, Lorenza, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4of3osft7c4f2o3a2lmabd1h4b